AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18566199 — intervention group
Group type: COMPARATOR
Intervention: Bair Hugger
Number of subjects: 184
Study 15988706 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg daily for 12 weeks
Number of subjects: 40
Study 15988706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 12699298 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium enhancement of estrogen's effects, with a recommended intake of 30 to 40 mmol Ca/d and sufficient vitamin D (approximately 25 microg vitamin D/d) to maintain serum 25(OH)D levels above 80 nmol/L.
Number of subjects: 0
Study 12699298 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and vitamin D supplementation in the presence of bone active agents.
Number of subjects: 0
Study 12699298 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer anabolic agents requiring higher levels of calcium repletion.
Number of subjects: 0
Study 10480774 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg alpha-lipoic acid intravenously for 3 weeks, followed by 600 mg alpha-lipoic acid three times a day orally for 6 months (A-A)
Number of subjects: 509
Study 10480774 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg alpha-lipoic acid intravenously for 3 weeks, followed by placebo three times a day orally for 6 months (A-P)
Number of subjects: 509
Study 10480774 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily intravenously for 3 weeks, followed by placebo three times a day orally for 6 months (P-P)
Number of subjects: 509
Study 7815337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine HCl (80 mg/70 kg p.o.)
Number of subjects: 5
Study 7815337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (20, 40, 80 and 120 mg/70 kg, oral and intranasal)
Number of subjects: 5
Study 7815337 — intervention group
Group type: COMPARATOR
Intervention: Triazolam (0.25 and 0.50 mg/70 kg p.o.)
Number of subjects: 5
Study 7815337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (oral and intranasal)
Number of subjects: 5
Study 7815337 — intervention group
Group type: COMPARATOR
Intervention: Triazolam
Number of subjects: 5
Study 7815337 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine (training dose)
Number of subjects: 5
Study 1745022 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysulfone membrane
Number of subjects: 0
Study 1745022 — intervention group
Group type: COMPARATOR
Intervention: Cuprophan membrane
Number of subjects: 0
Study 6980657 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam 0.3 mg kg‐1
Number of subjects: 16
Study 6980657 — intervention group
Group type: COMPARATOR
Intervention: thiopentone 3 mg kg‐1
Number of subjects: 16
Study 31869428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg s.c. for 3 days
Number of subjects: 793
Study 31869428 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg p.o. for 3 days
Number of subjects: 793
Study 31869428 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 10 mg for 10 days
Number of subjects: 793
Study 31869428 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 793
Study 30365262 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion + Metoclopramide (M)
Number of subjects: 266
Study 30365262 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion + Haloperidol (MH)
Number of subjects: 266
Study 30365262 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion + M (M)
Number of subjects: 266
Study 30365262 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion + MH (MH)
Number of subjects: 266
Study 30365262 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide (M)
Number of subjects: 266
Study 26869679 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine (MH) 10 mg
Number of subjects: 24
Study 26869679 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NAME 1 mg/kg
Number of subjects: 24
Study 26869679 — intervention group
Group type: COMPARATOR
Intervention: No drug (ND)
Number of subjects: 24
Study 24517155 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous hydrocortisone infusion (CSHI)
Number of subjects: 33
Study 24517155 — intervention group
Group type: COMPARATOR
Intervention: Oral hydrocortisone (OHC)
Number of subjects: 33
Study 22356132 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin + high-dose metformin
Number of subjects: 791
Study 22356132 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin + low-dose metformin
Number of subjects: 791
Study 22356132 — intervention group
Group type: EXPERIMENTAL
Intervention: high-dose metformin
Number of subjects: 791
Study 22356132 — intervention group
Group type: EXPERIMENTAL
Intervention: low-dose metformin
Number of subjects: 791
Study 22356132 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin
Number of subjects: 791
Study 22356132 — intervention group
Group type: EXPERIMENTAL
Intervention: open-label linagliptin + high-dose metformin
Number of subjects: 791
Study 22356132 — intervention group
Group type: EXPERIMENTAL
Intervention: linagliptin + metformin
Number of subjects: 791
Study 22356132 — intervention group
Group type: COMPARATOR
Intervention: metformin alone
Number of subjects: 791
Study 22356132 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 791
Study 19910547 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotor training (LT)
Number of subjects: 20
Study 19910547 — intervention group
Group type: COMPARATOR
Intervention: Clinical physical therapy (PT)
Number of subjects: 20
Study 17559146 — intervention group
Group type: EXPERIMENTAL
Intervention: IROX (oxaliplatin 85 mg/m² and irinotecan 200 mg/m² every 3 weeks)
Number of subjects: 383
Study 17559146 — intervention group
Group type: COMPARATOR
Intervention: FOLFOX (oxaliplatin with 5-fluorouracil)
Number of subjects: 383
Study 16293862 — intervention group
Group type: COMPARATOR
Intervention: CAF (cyclophosphamide, doxorubicin, and fluorouracil)
Number of subjects: 2690
Study 16293862 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 2690
Study 16293862 — intervention group
Group type: EXPERIMENTAL
Intervention: TAM (tamoxifen)
Number of subjects: 2690
Study 16293862 — intervention group
Group type: COMPARATOR
Intervention: No TAM
Number of subjects: 2690
Study 11740322 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin (7.5 mg/kg/dose twice a day for 7 days)
Number of subjects: 153
Study 11740322 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin (13.3 mg/kg/dose three times a day for 14 days)
Number of subjects: 153
Study 11740322 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 153
Study 11740322 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 153
Study 9542477 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole
Number of subjects: 10
Study 8061088 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta (2 MIU/day)
Number of subjects: 100
Study 8061088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 2646839 — intervention group
Group type: EXPERIMENTAL
Intervention: lotrolan (0.27 osmol/kg, 280 mg J/ml)
Number of subjects: 15
Study 2646839 — intervention group
Group type: EXPERIMENTAL
Intervention: lopromide (0.77 osmol/kg, 370 mg J/ml)
Number of subjects: 15
Study 2646839 — intervention group
Group type: EXPERIMENTAL
Intervention: Amidotrizoate (2.1 osmol/kg, 370 mg J/ml)
Number of subjects: 15
Study 2646839 — intervention group
Group type: COMPARATOR
Intervention: Amidotrizoate and lopromide
Number of subjects: 15
Study 31257160 — intervention group
Group type: EXPERIMENTAL
Intervention: MiRaDaSia model intervention
Number of subjects: 204
Study 31257160 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 204
Study 28662049 — intervention group
Group type: EXPERIMENTAL
Intervention: SD+AMX+MET (both 500mg x 3 times daily TID) for 3 days (group B)
Number of subjects: 102
Study 28662049 — intervention group
Group type: EXPERIMENTAL
Intervention: SD+AMX+MET (both 500mg x 3 times daily TID) for 7 days (group C)
Number of subjects: 102
Study 28662049 — intervention group
Group type: COMPARATOR
Intervention: SD within 2 consecutive days and placebo for 7 days (group A)
Number of subjects: 102
Study 26199386 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilengitide 2,000 mg administered intravenously twice weekly (arm A)
Number of subjects: 21
Study 26199386 — intervention group
Group type: COMPARATOR
Intervention: No treatment (arm B)
Number of subjects: 21
Study 26199386 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 21
Study 23922748 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrogenated soybean oil providing 15.7 g/day of TFA (trans18:1)
Number of subjects: 52
Study 23922748 — intervention group
Group type: COMPARATOR
Intervention: Control oil with mainly oleic acid
Number of subjects: 52
Study 22228829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 0
Study 22228829 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 19476825 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative fluid management (CON)
Number of subjects: 244
Study 19476825 — intervention group
Group type: EXPERIMENTAL
Intervention: Central venous catheter (CVC)
Number of subjects: 244
Study 19476825 — intervention group
Group type: COMPARATOR
Intervention: Fluid management (CON vs LIB)
Number of subjects: 244
Study 17429507 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic preparations and practice
Number of subjects: 0
Study 17429507 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic products
Number of subjects: 0
Study 17429507 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic knowledge of homeopathy
Number of subjects: 0
Study 15110885 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine oral rinse
Number of subjects: 0
Study 15110885 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine oral rinse
Number of subjects: 0
Study 11018619 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative biofeedback training with pelvic muscle exercise; Duration: 2 to 4 weeks before surgery; Frequency: Four times per day until surgery and resumed after catheter removal.
Number of subjects: 100
Study 11018619 — intervention group
Group type: COMPARATOR
Intervention: Control group performing pelvic muscle exercises without biofeedback; Received written and verbal instructions before surgery and after catheter removal.
Number of subjects: 100
Study 11018619 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups; Outcome measure: Rate of return of urinary control at 1, 2, 3, and 4 months after surgery.
Number of subjects: 100
Study 8857120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratracheal administration of preservative-free fentanyl
Number of subjects: 18
Study 8857120 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of preservative-free fentanyl
Number of subjects: 18
Study 8857120 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 18
Study 1542851 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (LD) radiotherapy: five times 2 Gy daily fractions to a total dose of 10 Gy
Number of subjects: 60
Study 1542851 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (HD) radiotherapy: ten times 2 Gy (8 patients) or five times 3.5 Gy (20 patients)
Number of subjects: 60
Study 1542851 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy initiated before and at postoperative day 4
Number of subjects: 60
Study 1542851 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy initiated after postoperative day 4
Number of subjects: 60
Study 1542851 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment outcome
Number of subjects: 60
Study 1542851 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment failures related to Brooker score
Number of subjects: 60
Study 4003286 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 34
Study 4003286 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate
Number of subjects: 34
Study 31423892 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive expert feedback (n=39)
Number of subjects: 73
Study 31423892 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=34)
Number of subjects: 73
Study 27522159 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral immunotherapy (E-OIT) at goal maintenance doses of 300 mg/d
Number of subjects: 40
Study 27522159 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral immunotherapy (E-OIT) at goal maintenance doses of 3000 mg/d
Number of subjects: 40
Study 27522159 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral immunotherapy (E-OIT) overall
Number of subjects: 40
Study 27522159 — intervention group
Group type: EXPERIMENTAL
Intervention: Early oral immunotherapy (E-OIT)
Number of subjects: 40
Study 27522159 — intervention group
Group type: COMPARATOR
Intervention: Matched standard-care controls
Number of subjects: 40
Study 25794018 — intervention group
Group type: EXPERIMENTAL
Intervention: Upward advancement of the nasolabial components (NA group)
Number of subjects: 73
Study 25794018 — intervention group
Group type: COMPARATOR
Intervention: No upward advancement of the nasolabial components (LA group)
Number of subjects: 73
Study 25433494 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-care manager intervention (adapted)
Number of subjects: 0
Study 22727868 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood glucose screening using a standard protocol and glucose oxidase method in the first 48 hours after birth
Number of subjects: 514
Study 19547761 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative gabapentin (GBP) 100 mg three times per day (G3)
Number of subjects: 40
Study 19547761 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative gabapentin (GBP) 200 mg three times per day (G4)
Number of subjects: 40
Study 19547761 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative gabapentin (GBP) 300 mg three times per day (G5)
Number of subjects: 40
Study 19547761 — intervention group
Group type: COMPARATOR
Intervention: Preoperative gabapentin 600 mg/postoperative placebo (G2)
Number of subjects: 40
Study 19547761 — intervention group
Group type: COMPARATOR
Intervention: Preoperative placebo/postoperative placebo (G1)
Number of subjects: 40
Study 17306709 — intervention group
Group type: EXPERIMENTAL
Intervention: Stentless biological valve
Number of subjects: 48
Study 17306709 — intervention group
Group type: COMPARATOR
Intervention: Stented biological valve
Number of subjects: 48
Study 17306709 — intervention group
Group type: COMPARATOR
Intervention: Tilting disc mechanical valve
Number of subjects: 48
Study 17306709 — intervention group
Group type: COMPARATOR
Intervention: Bileaflet mechanical valve
Number of subjects: 48
Study 15076170 — intervention group
Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg/day
Number of subjects: 25
Study 12766931 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefazodone 100mg bd
Number of subjects: 49
Study 12766931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 10489824 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukotriene antagonist
Number of subjects: 281
Study 10489824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281
Study 8728530 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-Stirrup brace
Number of subjects: 26
Study 8728530 — intervention group
Group type: EXPERIMENTAL
Intervention: Adhesive tape
Number of subjects: 26
Study 8728530 — intervention group
Group type: COMPARATOR
Intervention: No support (control)
Number of subjects: 26
Study 1713987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (0.06 mg/kg/min)
Number of subjects: 10
Study 1713987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6981165 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis alone (trimethoprim‐sulfamethoxazole or nitrofurantoin)
Number of subjects: 30
Study 6981165 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial prophylaxis plus corrective surgery
Number of subjects: 30
Study 6981165 — intervention group
Group type: COMPARATOR
Intervention: Antimicrobial prophylaxis alone (control group)
Number of subjects: 30
Study 2580712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcainide (2 mg/kg)
Number of subjects: 19
Study 2580712 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (100 mg)
Number of subjects: 19
Study 2580712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 29481391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intercostal and pectoral nerve blocks with 0.25% bupivacaine with 1:200,000 epinephrine and 4 mg of dexamethasone
Number of subjects: 47
Study 29481391 — intervention group
Group type: COMPARATOR
Intervention: Sham nerve blocks with normal saline
Number of subjects: 47
Study 29481391 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative intercostal and pectoral nerve blocks
Number of subjects: 47
Study 27855103 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA)‐selection of sperm (physiological intracytoplasmic sperm injection, PICSI)
Number of subjects: 0
Study 27855103 — intervention group
Group type: COMPARATOR
Intervention: Conventional sperm selection methods (ICSI)
Number of subjects: 0
Study 27855103 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA)‐selection of sperm
Number of subjects: 0
Study 25336055 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic Epidural Analgesia (TEA)
Number of subjects: 132
Study 25336055 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus Sheath Catheters (RSC)
Number of subjects: 132
Study 23563024 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA 1 g daily
Number of subjects: 52
Study 23563024 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 52
Study 20681808 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading
Number of subjects: 60
Study 20681808 — intervention group
Group type: COMPARATOR
Intervention: Conventional loading
Number of subjects: 60
Study 20681808 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 17962632 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 0
Study 17962632 — intervention group
Group type: COMPARATOR
Intervention: Medical cohort (control)
Number of subjects: 0
Study 17491171 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-administered questionnaires
Number of subjects: 213
Study 17491171 — intervention group
Group type: COMPARATOR
Intervention: Telephone-administered questionnaires
Number of subjects: 213
Study 14605015 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic therapy (enoxaparin or unfractionated heparin in combination with tirofiban or placebo) for 2 to 8 days in TETAMI randomized patients.
Number of subjects: 2737
Study 14605015 — intervention group
Group type: EXPERIMENTAL
Intervention: Reperfusion therapy (lytic or primary PCI) in registry patients who received reperfusion.
Number of subjects: 2737
Study 14605015 — intervention group
Group type: COMPARATOR
Intervention: Registry patients who did not receive reperfusion therapy.
Number of subjects: 2737
Study 11027741 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of melatonin
Number of subjects: 7
Study 11027741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 11027741 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of melatonin followed by 0.5 mg per day
Number of subjects: 7
Study 8914777 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium therapy
Number of subjects: 0
Study 8914777 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 1410588 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinamide (1-6 g oral doses)
Number of subjects: 4
Study 6232524 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study 6232524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine chewing-gum
Number of subjects: 0
Study 6232524 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 31522217 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided continuous fascia iliaca compartment block (FICB) for preoperative analgesia
Number of subjects: 85
Study 31522217 — intervention group
Group type: COMPARATOR
Intervention: Fake (or generic) continuous FICB
Number of subjects: 85
Study 30256065 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming protocol using Xbox 360® with Kinect® and the game 'Your Shape Fitness Evolved'
Number of subjects: 38
Study 30256065 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exergaming)
Number of subjects: 38
Study 27067706 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel urine pregnancy test (MLPT)
Number of subjects: 600
Study 27067706 — intervention group
Group type: COMPARATOR
Intervention: High sensitivity urine pregnancy test (HSPT)
Number of subjects: 600
Study 25300037 — intervention group
Group type: EXPERIMENTAL
Intervention: START intervention (manual-based coping strategy programme)
Number of subjects: 260
Study 22994617 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor intervention programme (60 minutes of exercises, three times per week for 6 months)
Number of subjects: 32
Study 22994617 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor intervention programme
Number of subjects: 32
Study 22994617 — intervention group
Group type: COMPARATOR
Intervention: Control group (no motor intervention)
Number of subjects: 32
Study 19826403 — intervention group
Group type: EXPERIMENTAL
Intervention: Rexin-G (dose 0-1)
Number of subjects: 9
Study 19826403 — intervention group
Group type: EXPERIMENTAL
Intervention: Rexin-G (dose 2)
Number of subjects: 9
Study 16614849 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine (1,200 mg/m²) as a 2-h continuous infusion (10 mg/m² per min) on days 1 and 8 of each cycle plus AUC 5 carboplatin on day 1, repeated every 21 days.
Number of subjects: 54
Study 16614849 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine plus carboplatin
Number of subjects: 54
Study 16099700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline monotherapy
Number of subjects: 573